The purpose of this study is to evaluate the mass balance and safety of \[14C\] ABBV-903 in healthy male volunteers following a single oral dose administration.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
7
Solution; Oral
Fortrea Clinical Research Unit Inc. /ID# 253962
Madison, Wisconsin, United States
Maximum observed concentration (Cmax) of ABBV-903
Cmax of ABBV-903 will be assessed.
Time frame: Up to Day 16
Time to Cmax (peak time, Tmax) of ABBV-903
Tmax of ABBV-903 will be assessed.
Time frame: Up to Day 16
Terminal Phase Elimination Half-life (t1/2) of ABBV-903
Terminal phase elimination half-life (t1/2) will be assessed.
Time frame: Up to Day 16
Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of ABBV-903
AUC0-t of ABBV-903 will be assessed.
Time frame: Up to Day 16
AUC from Time 0 to Infinite Time (AUC0-t) of ABBV-903
AUC0-inf of ABBV-903 will be assessed.
Time frame: Up to Day 16
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Baseline to Day 46
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.